These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21083069)

  • 41. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 42. Celera buys Axys.
    Morrison C
    Nat Biotechnol; 2001 Aug; 19(8):703-5. PubMed ID: 11479548
    [No Abstract]   [Full Text] [Related]  

  • 43. Biotech bonanza.
    Stipp D
    Fortune; 1999 Nov; 140(9):333-4. PubMed ID: 10623111
    [No Abstract]   [Full Text] [Related]  

  • 44. Industry warily eyes new Medicare drug plan.
    Vastag B
    Nat Biotechnol; 2006 Feb; 24(2):120. PubMed ID: 16465141
    [No Abstract]   [Full Text] [Related]  

  • 45. Is there balm in Gilead?
    Jacobs T
    Nat Biotechnol; 2006 Dec; 24(12):1478. PubMed ID: 17160040
    [No Abstract]   [Full Text] [Related]  

  • 46. The production capacity bottleneck.
    De Keyser JL
    Nat Biotechnol; 2001 Aug; 19(8):715. PubMed ID: 11479555
    [No Abstract]   [Full Text] [Related]  

  • 47. Swooping for biotech.
    Wadman M
    Nature; 2005 Sep; 437(7058):475. PubMed ID: 16177760
    [No Abstract]   [Full Text] [Related]  

  • 48. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 49. Cetus and Chiron merge.
    Gershon D
    Nature; 1991 Aug; 352(6334):364. PubMed ID: 1861710
    [No Abstract]   [Full Text] [Related]  

  • 50. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

  • 51. Value creation and sharing among universities, biotechnology and pharma.
    Edwards MG; Murray F; Yu R
    Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
    [No Abstract]   [Full Text] [Related]  

  • 52. Biotech acquisitions by big pharma: why and what is next.
    Malik NN
    Drug Discov Today; 2009 Sep; 14(17-18):818-21. PubMed ID: 19584004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nasdaq restructures biotech index.
    Morrison C
    Nat Biotechnol; 2001 Mar; 19(3):187. PubMed ID: 11231518
    [No Abstract]   [Full Text] [Related]  

  • 54. Biotech at the beauty counter.
    Nasto B
    Nat Biotechnol; 2007 Jun; 25(6):617-9. PubMed ID: 17557090
    [No Abstract]   [Full Text] [Related]  

  • 55. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 56. Europe discovers bioentrepreneurship.
    Haycock P
    Nat Biotechnol; 1998 May; 16 Suppl():6. PubMed ID: 9591249
    [No Abstract]   [Full Text] [Related]  

  • 57. The lengthening handshake.
    Osborne R
    Nat Biotechnol; 2010 Mar; 28(3):197-9. PubMed ID: 20212476
    [No Abstract]   [Full Text] [Related]  

  • 58. Acquisition signals shift from US market.
    Mitchell P
    Nat Biotechnol; 2005 Jun; 23(6):635. PubMed ID: 15940218
    [No Abstract]   [Full Text] [Related]  

  • 59. Bioscience industry in metro Atlanta.
    Allen CR
    Drug Discov Today; 2005 Feb; 10(4):237-9. PubMed ID: 15708740
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The three pillars of bioentrepreneurship.
    Schoemaker HJ; Schoemaker AF
    Nat Biotechnol; 1998 May; 16 Suppl():13-5. PubMed ID: 9591253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.